Nevertheless, we summarized all currently available clinical data on bone health-related events in clinical trials (Supplementary Fig. 9a), and found that patients with PARP inhibitor treatment showed a trend of higher risk of bone fracture, serious bone, or musculoskeletal pain, as well as osteoporosis/osteonecrosis, compared with patients with Physician’s Choice Treatment or Placebo (Supplementary Fig. 9b). This evidence concerns the gene PARP1 and osteoporosis.